PuraPharm Corporation Limited

1498

KYG7306Y1044

Pharmaceuticals

Delayed Hong Kong S.E. Other stock markets 04:08:22 2024-04-29 am EDT			5-day change	1st Jan Change
0.73 ^HKD	-2.67%		-2.67%	-18.89%

Apr. 01	PuraPharm's Net Loss Shrinks in 2023; Revenue Falls 9%	MT
Mar. 28	PuraPharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	CI

PuraPharm Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2022

August 28, 2022 at 07:25 am EDT

PuraPharm Corporation Limited reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was HKD 230.76 million compared to HKD 302.76 million a year ago. Net loss was HKD 39.9 million compared to net income of HKD 11.97 million a year ago.

Basic loss per share from continuing operations was HKD 0.1012 compared to basic earnings per share from continuing operations of HKD 0.0304 a year ago. Diluted loss per share from continuing operations was HKD 0.1012 compared to diluted earnings per share from continuing operations of HKD 0.0304 a year ago.

Latest news about PuraPharm Corporation Limited

PuraPharm's Net Loss Shrinks in 2023; Revenue Falls 9%	Apr. 01	MT
PuraPharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
PuraPharm Corporation Limited Announces Cessation of Norimoto Hisayoshi as Executive Director	Nov. 20	CI
PuraPharm Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-29	CI
PuraPharm Corporation Limited Announces Appointment of Leung Stephen Kwok Keung as Non-Executive Director	23-06-14	CI
PuraPharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-21	CI
PuraPharm Grants Nearly 8 Million Options	22-12-30	MT
Purapharm Swings to H1 Loss on Lower Sales	22-08-28	MT
PuraPharm Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-28	CI
Purapharm Corporation Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended June 30, 2022	22-08-12	CI
Purapharm Corporation Limited Announces Retirement of Non-Executive Director	22-03-31	CI
Purapharm Turns to Loss in 2021 on Impairment Loss of Goodwill; Shares Fall 4%	22-03-30	MT
PuraPharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-29	CI
Purapharm Forecasts Turn to Loss in 2021	22-02-28	MT
PuraPharm Corporation Limited Provides Earnings Guidance for the Year Ending December 31, 2021	22-02-25	CI
Purapharm Corporation Limited Announces Change of Headquarter And principal Place of Business in Hong Kong	21-12-16	CI
Purapharm : Cancels Sale of Intellectual Property Assets to BAGI Research	21-10-06	MT
PuraPharm : Books Higher Profit, Revenue in H1	21-08-23	MT
Purapharm Corporation Limited Reports Earnings Results for the Half Year Ended June 30, 2021	21-08-20	CI
PuraPharm Corporation Limited Announces Change of CFO	21-07-29	CI
Purapharm Corporation Limited Announces Executive Changes	21-07-29	CI
Purapharm Corporation Limited Announces Re-Designation of Cheong Shin Keong from an Executive Director to Non-Executive Director	21-06-28	CI
PuraPharm Corporation Limited Announces Retirement of Directors and Change in Composition of the Board Committees	21-05-28	CI
Purapharm : Extends Long Stop Date of Intellectual Property Asset Sale	21-03-26	MT
Purapharm Corporation Limited Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-25	CI

Chart PuraPharm Corporation Limited

Duration

Period

More charts

Company Profile

PuraPharm Corporation Ltd is an investment holding company principally engaged in the concentrated Chinese medicine granule (CCMG) businesses. The Company operates through five business segments. The China CCMG segment is mainly engaged in the production and sales of CCMG products in China. The Hong Kong CCMG segment is mainly engaged in the sales of CCMG products, excluding the sales through self-operated clinics in Hong Kong. The Chinese Healthcare Products segment is mainly engaged in the production and sales of healthcare products in Hong Kong and China. The Clinics segment is mainly engaged in the provision of Chinese medical diagnostic services and sales of CCMG products through self-operated clinics. The Plantation segment is mainly engaged in the plantation and trading of raw Chinese herbs, and the manufacture and sale of traditional Chinese medicine (TCM) decoction pieces.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
PURAPHARM CORPORATION LIMITED	-18.89%	37.85M
DONG-E-E-JIAO CO.,LTD.	+37.08%	5.92B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-17.43%	4.51B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.46%	3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+0.51%	3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-3.53%	2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+41.15%	1.97B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-5.15%	1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-10.38%	1.53B

Alternative Medicine